Berton Guillaume, Hospital Marie-Anne, Garciaz Sylvain, Rouzaud Camille, Maisano Valerio, Hicheri Yosr, D'Incan Corda Evelyne, Rey Jerome, Bisbal Magali, Sannini Antoine, Chine Laurent Chow, Servan Luca, Gonzalez Frederic, Vey Norbert, Mokart Djamel, Saillard Colombe
Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, France.
Intensive Care Unit, Institut Paoli-Calmettes, Marseille, France.
Eur J Haematol. 2025 Apr;114(4):679-689. doi: 10.1111/ejh.14366. Epub 2025 Jan 6.
Acute myeloid leukemias (AMLs) are the hematological malignancies with the highest need for intensive care unit (ICU) admission due to their association with various life-threatening situations. Limited data exist regarding the outcomes of elderly individuals with AML admitted to the ICU. However, current therapeutic protocols offer the potential for extended survival in this population. This retrospective, monocentric study focused on the outcomes of individuals aged ≥ 60 years admitted to the ICU for newly diagnosed AML. It included 139 patients admitted to the ICU at the Paoli-Calmettes Institute between April 2010 and October 2020, during the initial phase of AML management. Patients were categorized into three groups based on the presence of biological criteria indicating "high risk" for complications (thrombocytopenia < 50 000/mm and leukocytosis > 50 000/mm) and organ failure. Multiple logistic regression models were employed to identify predictive factors for in-hospital and day 90 mortality, while Cox regression was used for 1-year mortality. The rates of in-hospital, day 90, and 1-year mortality were 37%, 42%, and 60%, respectively. Variables associated with in-hospital mortality included the Charlson Comorbidity Index, the need for invasive mechanical ventilation (MV), and multi-organ failure. ELN17 risk was significantly associated with 1-year mortality rates. This study demonstrates the benefits of ICU management for individuals aged ≥ 60 years during the initial phase of AML. It illustrates the effects of age, comorbidities, and the severity of organ failures on short-term mortality and highlights the impact of classical prognostic markers on long-term mortality.
急性髓系白血病(AML)是因与各种危及生命的情况相关而最需要入住重症监护病房(ICU)的血液系统恶性肿瘤。关于入住ICU的老年AML患者的预后数据有限。然而,当前的治疗方案为该人群延长生存期提供了可能。这项回顾性单中心研究聚焦于因新诊断AML入住ICU的≥60岁患者的预后。研究纳入了2010年4月至2020年10月期间在保利 - 卡尔梅特研究所AML治疗初始阶段入住ICU的139例患者。根据表明并发症“高风险”(血小板减少<50000/mm且白细胞增多>50000/mm)和器官衰竭的生物学标准,将患者分为三组。采用多个逻辑回归模型确定住院和90天死亡率的预测因素,而采用Cox回归分析1年死亡率。住院、90天和1年死亡率分别为37%、42%和60%。与住院死亡率相关的变量包括查尔森合并症指数、有创机械通气(MV)需求和多器官衰竭。欧洲白血病网络(ELN)17风险与1年死亡率显著相关。本研究证明了在AML初始阶段对≥60岁患者进行ICU管理的益处。它阐明了年龄、合并症和器官衰竭严重程度对短期死亡率的影响,并突出了经典预后标志物对长期死亡率的影响。